Targeted Therapies for Melanoma Brain Metastases

Current Treatment Options in Neurology

Volumn 19, Issue 4, 2017, Pages

  Berghoff, Anna S ^a   Preusser, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

BRAF inhibitor; Brain metastases; Immune checkpoint inhibitor; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BIOLOGICAL MARKER; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; UNCLASSIFIED DRUG;

BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLITIS; DIARRHEA; DRUG EFFICACY; FATIGUE; FEVER; HUMAN; HYPERKERATOSIS; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; KERATOACANTHOMA; MELANOMA METASTASIS; MOLECULARLY TARGETED THERAPY; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODERMATOSIS; PNEUMONIA; RASH; REVIEW; SKIN MANIFESTATION; SQUAMOUS CELL SKIN CARCINOMA; THYROIDITIS; VOMITING;

EID: 85016956793     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-017-0449-2     Document Type: Review

References (73)

1. Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S. Evolving treatment options for melanoma brain metastases. Lancet Oncol. 2015;16(13):E486–497. doi:10.1016/S1470-2045(15)00141-2.
2. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660–8.
3. Amin A, Lawson DH, Salama AK, Koon HB, Guthrie Jr T, Thomas SS, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated bBRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44. doi:10.1186/S40425-016-0148-7.
4. Atefi MS, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, et al. Effects of MAPK and PI3k pathways on PD-L1 expression in melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2014. doi:10.1158/1078-0432.Ccr-13-2797.
5. Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol. 2015;42(3):363–77. doi:10.1053/J.Seminoncol.2015.02.015.
6. Basnet A, Saad N, Benjamin S. A case of vanishing brain metastasis in a melanoma patient on nivolumab. Anticancer Res. 2016;36(9):4795–8. doi:10.21873/Anticanres.11038.
7. Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. 2014. doi:10.1111/His.12537.
8. Berghoff AS, Preusser M. The inflammatory microenvironment in brain metastases: potential treatment target? Chin Clin Oncol. 2015;4(2):21. doi:10.3978/J.Issn.2304-3865.2015.06.03.
9. Berghoff AS, Venur VA, Preusser M, Ahluwalia MS. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book / Asco Am Soc Clin Oncol Meet. 2016;35:E116–122. doi:10.14694/Edbk_100005.
10. Berghoff AS, Schur S, Fureder LM, Gatterbauer B, Dieckmann K, Widhalm G, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016;1(2):E000024. doi:10.1136/Esmoopen-2015-000024.
11. Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123(2):223–33. doi:10.1007/S00401-011-0887-Y.
12. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al. Assessment of braf V600e mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11–9. doi:10.1007/S00401-011-0841-Z.
13. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(21):5537–46. doi:10.1158/1078-0432.Ccr-13-3003.
14. Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res. 2016;4(3):179–82. doi:10.1158/2326-6066.Cir-15-0160.
15. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13(9):879–86. doi:10.1016/S1470-2045(12)70324-8.
16. Franceschini D, Franzese C, Navarria P, Ascolese AM, De Rose F, Del Vecchio M, et al. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? Cancer Treat Rev. 2016;50:1–8. doi:10.1016/J.Ctrv.2016.08.003.
17. Frenard C, Peuvrel L, Jean MS, Brocard A, Knol AC, Nguyen JM, et al. Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. J Neurooncol. 2016;126(2):355–60. doi:10.1007/S11060-015-1977-9.
18. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):E542–51. doi:10.1016/S1470-2045(16)30406-5.
19. •• Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–83. doi:10.1016/S1470-2045(16)30053-5. First phase II study on pembrolizumab monotherapy in patients with brain metastaes either from non-small cell lung cancer or melnaoma.
20. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase Ii trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204. doi:10.1186/1479-5876-9-204.
21. Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011;28(4):1140–4. doi:10.1007/S12032-010-9606-0.
22. Haueis SA, Kranzlin P, Mangana J, Cheng PF, Urosevic-Maiwald M, Braun RP, et al. Does the distribution pattern of brain metastases during braf inhibitor therapy reflect phenotype switching? Melanoma Res. 2017. doi:10.1097/Cmr.0000000000000338.
23. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65. doi:10.1016/S0140-6736(12)60868-X.
24. Hodi FS, O’day SJ, Mcdermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/Nejmoa1003466.
25. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–8. doi:10.1200/Jco.2015.60.8448.
26. • Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368–75. doi:10.1016/J.Ijrobp.2015.01.004.Clinical study on the combiantion of iplimumab and sterotatic radiosurgery in patients with melanoma brain metastases.
27. Kirchberger MC, Hauschild A, Schuler G, Heinzerling L. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Eur J Cancer. 2016;65:182–4. doi:10.1016/J.Ejca.2016.07.003.
28. Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, et al. Characterization Of PD-L1 expression and associated T-Cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. 2015;21(13):3052–60. doi:10.1158/1078-0432.Ccr-14-3073.
29. Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev. 2016;53:25–37. doi:10.1016/J.Ctrv.2016.11.013.
30. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in braf-mutated melanoma. N Engl J Med. 2014;371(20):1867–76. doi:10.1056/Nejmoa1408868.
31. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey C, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/Nejmoa1504030.
32. Lin NU, Winer EP. Brain metastases: the Her2 paradigm. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(6):1648–55. doi:10.1158/1078-0432.Ccr-06-2478.
33. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34(8):871–8. doi:10.1200/Jco.2015.62.9345.
34. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (Break-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95. doi:10.1016/S1470-2045(12)70431-X.
35. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17(12):1743–54. doi:10.1016/S1470-2045(16)30578-2.
36. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239–46. doi:10.1200/Jco.2010.32.4327.
37. Luttmann N, Gratz V, Haase O, Eckey T, Langan EA, Zillikens D, et al. Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition. Melanoma Res. 2016;26(5):528–31. doi:10.1097/Cmr.0000000000000270.
38. Ma MW, Qian M, Lackaye DJ, Berman RS, Shapiro RL, Pavlick AC, et al. Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. Neuro Oncol. 2012;14(7):849–58. doi:10.1093/Neuonc/Nos113.
39. Margolin K, Ernstoff MS, Hamid O, Lawrence D, Mcdermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65. doi:10.1016/S1470-2045(12)70090-6.
40. Margolin K. The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr Treat Options Oncol. 2016;17(9):48. doi:10.1007/S11864-016-0421-5.
41. •• Mcarthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2. Multicentre Stud Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2016. doi:10.1093/Annonc/Mdw641. Phase II study on Vemurafenib monotherapy in patients with melanoma brain metastases.
42. Mcarthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32. doi:10.1016/S1470-2045(14)70012-9.
43. Migliorini D, Fertani S, Dietrich PY. Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing? CNS Oncol. 2016;5(4):199–201. doi:10.2217/Cns-2016-0019.
44. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF. Mechanisms limiting distribution of the threonine-protein kinase B-Raf(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013;344(3):655–64. doi:10.1124/Jpet.112.201475.
45. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol. 2013;113(3):411–6. doi:10.1007/S11060-013-1127-1.
46. Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, et al. PI3k pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(23):5818–28. doi:10.1158/1078-0432.Ccr-16-0064.
47. • Patel BG, Ahmed KA, Johnstone PA, Yu HH, Etame AB. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res. 2016;26(4):382–6. doi:10.1097/Cmr.0000000000000250. Case series on the combination of BRAF and MEK inhibition with radiosurgery in patients with melanoma brain metastases.
48. Peuvrel L, Saint-Jean M, Quereux G, Brocard A, Khammari A, Knol AC, et al. Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib. J Neurooncol. 2014;120(1):147–54. doi:10.1007/S11060-014-1533-Z.
49. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31. doi:10.1056/Nejmoa1112824.
50. Preusser M, Winkler F, Collette L, Haller S, Marreaud S, Soffietti R, et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer. 2012;48(18):3439–47. doi:10.1016/J.Ejca.2012.07.002.
51. Preusser M, Capper D, Hartmann C, Euro CNSRC. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol. 2011;30(5):217–30.
52. Preusser M, Berghoff AS, Thallinger C, Zielinski CC. Cancer immune cycle: a video introduction to the interaction between cancer and the immune system. ESMO Open. 2016;1(3):E000056. doi:10.1136/Esmoopen-2016-000056.
53. Qian JM, Yu JB, Kluger H, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016;122(19):3051–8. doi:10.1002/Cncr.30138.
54. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–6. doi:10.1056/Nejmc1302338.
55. Richtig E, Asslaber M, Partl R, Avian A, Berghold A, Kapp K, et al. Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types. Clin Neuropathol. 2016;35(2):89–92. doi:10.5414/Np300903.
56. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(7):1965–77. doi:10.1158/1078-0432.Ccr-13-3122.
57. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. doi:10.1056/Nejmoa1412082.
58. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. doi:10.1056/Nejmoa1503093.
59. Robert C, Thomas L, Bondarenko I, O’day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. doi:10.1056/Nejmoa1104621.
60. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17. doi:10.1016/S0140-6736(14)60958-2.
61. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields J. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol. 2011;98(3):394–9. doi:10.1016/J.Radonc.2010.12.017.
62. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase Ii and phase Iii trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94. doi:10.1200/Jco.2014.56.2736.
63. Seifert H, Hirata E, Gore M, Khabra K, Messiou C, Larkin J, et al. Extrinsic factors can mediate resistance to braf inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res. 2016;29(1):92–100. doi:10.1111/Pcmr.12424.
64. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99. doi:10.1056/Nejmoa1406498.
65. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011. doi:10.1200/Jco.2011.38.0527.
66. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293–5. doi:10.1016/J.Ijrobp.2012.03.017.
67. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, Mcdermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/Nejmoa1200690.
68. Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF. Factors influencing the CNS distribution of a novel MEK-1/2 Inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos. 2014;42(8):1292–300. doi:10.1124/Dmd.114.058339.
69. • Van Allen E, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207–11. doi:10.1126/Science.Aad0095. Study on the tumor tissue based genomic alteration correlating with response to CTLA4 blockade. Study on the tumor tissue based genomic alteration correlating with response to CTLA4 blockade.
70. Weber JS, Yu B, Kudchadkar RR, Gallenstein D, Ce H, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–8. doi:10.1200/Jco.2013.51.4802.
71. Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2012;23 Suppl 8:Viii15–21. doi:10.1093/Annonc/Mds258.
72. Wolchok JD, Hoos A, O’day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(23):7412–20. doi:10.1158/1078-0432.Ccr-09-1624.
73. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. doi:10.1056/Nejmoa1302369.